70.90 -0.12 (-0.17%)
After hours: 4:59PM EST
|Bid||71.00 x 1200|
|Ask||71.15 x 800|
|Day's Range||70.79 - 74.00|
|52 Week Range||70.09 - 110.81|
|Beta (3Y Monthly)||1.49|
|PE Ratio (TTM)||19.75|
|Earnings Date||Jan 23, 2019 - Jan 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||108.23|
Nine companies have majority ‘buy’ ratings, with upside potential of as much as 123%, according to analysts.
Consider Gilead Sciences (GILD) and Celgene (CELG) for example. At recent prices of $70 and $75, they traded at market values that aren’t too far above the value of their operating businesses, according to discounted cash flow analysis by Jefferies biotech analyst Michael Yee and his team. Then add if they fall back to their “free pipeline” stock prices.
Prothena (PRTA) posts narrower-than-expected loss in the third quarter. With the failure of lead drug, NEOD001, the focus is now on its mid-stage candidate, prasinezumab.
US voters have delivered a split verdict in midterm elections for Congress. Democrats regained a majority of seats in the House of Representatives but Republicans have retained control of the Senate, where they are on course for a net gain of at least three seats. Donald Trump boasted at a press conference on Wednesday about how his campaigning paid off for multiple candidates in the midterm elections.
Biogen Inc. (NASDAQ: BIIB) fell alongside the broad market selloff in October, but Biogen stock rallied rebounded when it reported third-quarter results. With BIIB stock price still in value territory at 15 times earnings and 11 times forward earnings, investors should take a closer look at the latest results.
Agios' (AGIO) loss tops estimates in Q3. Its precision medicine Tibsovo's performance in the very first quarter after approval in July leads to a significant year-over-year revenue growth.
bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.
Celgene Corporation (CELG) plans to present at two upcoming investor events where Celgene management will provide an overview of the Company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Presentations will cover a wide range of blood diseases including multiple myeloma, lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndromes and be
The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals
Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Merck’s revenues grew 5% YoY (year-over-year) to $10.8 billion in the third quarter. Its net revenues were $31.3 billion in the first nine months of the year compared to $29.7 billion in the first nine months of 2017, reflecting a ~5% YoY growth.
On October 25, Merck & Co. (MRK) announced a dividend of $0.55 per share for its outstanding common stock in the fourth quarter of 2018. That’s a ~15% increase from its dividend of $0.48 per share in the fourth quarter of 2017.
NEW YORK, Oct. 31, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.